20 min listen
Investigational Dual PPAR Agonist, FXR Agonist With Fibrate, and Hyperlipidemia in People With PBC: Conference Coverage of AASLD
Investigational Dual PPAR Agonist, FXR Agonist With Fibrate, and Hyperlipidemia in People With PBC: Conference Coverage of AASLD
ratings:
Length:
9 minutes
Released:
Dec 6, 2023
Format:
Podcast episode
Description
During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Marlyn J. Mayo, MD, discusses topline results from several of these studies and more, including: A phase III study of an investigational dual PPAR α/δ agonist (elafibranor) in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid (UDCA)A study that evaluated the effectiveness and safety of second-line therapy in PBC where obeticholic acid with or without a fibrate was added to the treatment regimen of people with PBC with an incomplete response to UDCAA retrospective review of the rates of hyperlipidemia, atherosclerosis, and/or hepatic steatosis in patients with PBCPresenter: Marlyn J. Mayo, MDProfessor of Internal MedicineDivision of Digestive & Liver DiseasesUT Southwestern Medical CenterDallas, TexasLink to commentary:Coming Soon!Link to reviews of other PBC studies from AASLD 2023: https://bit.ly/3RvXXEI
Released:
Dec 6, 2023
Format:
Podcast episode
Titles in the series (100)
Benefits of and Need for Integrated Addiction and Infectious Disease Care: Listen to an insightful discussion between infectious disease experts, Christian B. Ramers, MD, MPH, and Sandra Springer, MD, on current evidence supporting the need for integrated addiction and infectious disease care services. by CCO Infectious Disease Podcast